18 results on '"Bezinelli, Leticia Mello"'
Search Results
2. Dentistry consensus on HSCT – Part III: Special topics – Dentistry on HSCT
- Author
-
Santos, Paulo Sérgio da Silva, Granzotto, Fabiana Caramori Noal, Antunes, Héliton Spindola, de Lima, Emilze Mafra, Varanda, Renata de Freitas, Maccari, Karina, Bezinelli, Leticia Mello, Melo, Walmyr Ribeiro, Junior, Luiz Alberto Valente Soares, De Macedo, Leandro Dorigan, and Eduardo, Fernanda de Paula
- Published
- 2023
- Full Text
- View/download PDF
3. Brazilian dental consensus on dental management in hematopoietic stem cell transplantation – Part I – pre-HSCT
- Author
-
Correa, Maria Elvira Pizzigati, Granzotto, Fabiana Caramori Noal, Innocentini, Lara Maria Alencar Ramos, Reis, Thiago de Carvalho, de Lima, Emilze Mafra, Varanda, Renata de Freitas, Santos, Paulo Sérgio da Silva, Junior, Luiz Alberto Valente Soares, Bezinelli, Leticia Mello, Eduardo, Fernanda de Paula, Melo, Walmyr Ribeiro, Antunes, Héliton Spíndola, and De Macedo, Leandro Dorigan
- Published
- 2023
- Full Text
- View/download PDF
4. Effectiveness of Toothpastes on SARS-CoV-2 Viral Load in Saliva
- Author
-
Eduardo, Fernanda P, Corrêa, Luciana, Mansur, Fernanda, Benitez, Carlos, Hamerschlak, Nelson, Pinho, João Renato Rebello, Heller, Debora, and Bezinelli, Letícia Mello
- Published
- 2022
- Full Text
- View/download PDF
5. Self-collected unstimulated saliva, oral swab, and nasopharyngeal swab specimens in the detection of SARS-CoV-2
- Author
-
de Paula Eduardo, Fernanda, Bezinelli, Leticia Mello, de Araujo, Carlos Ariel Rodrigues, Moraes, João Vitor Vanderlan, Birbrair, Alexander, Pinho, João Renato Rebello, Hamerschlak, Nelson, Al-Hashimi, Ibtisam, and Heller, Debora
- Published
- 2022
- Full Text
- View/download PDF
6. Oral Mucositis and Nutritional Status in Children Who Underwent Hematopoietic Cell Transplantation: A Comparison Between Nonmalignant and Malignant Primary Diseases.
- Author
-
de Castro, Fabíola Germano, de Paula Eduardo, Fernanda, Bezinelli, Leticia Mello, Hamerschlak, Nelson, Netto, Gabriele Zamperlini, Fernandes, Juliana Folloni, and Corrêa, Luciana
- Subjects
MUCOSITIS ,HEMATOPOIETIC stem cell transplantation ,NUTRITIONAL status ,WEIGHT gain ,WEIGHT loss ,BODY weight ,CHILD patients - Abstract
Background: There is a lack of studies analyzing the association between oral mucositis (OM) and nutritional imbalance in children during hematopoietic stem cell transplantation (HSCT). The aim of this study was to compare the risk factors for OM and nutritional imbalance during HSCT in pediatric patients with nonmalignant diseases (NMD) and malignant diseases (MD). Methods: Data on age, sex, primary disease, transplantation type, conditioning regimen, GVHD prophylaxis, gastrointestinal toxicity, OM, percent body weight loss or gain, nutritional repositioning, and overall survival (OS) were retrospectively collected from the 132 medical records. The data were then compared between patients with NMD (n = 70) and MD (n = 62). Results: OM had a similar severity between the groups. The primary risk factor for OM in the NMD group was the conditioning regimen with busulfan, while in the MD group it was GVHD prophylaxis with cyclosporin and methotrexate. OM did not have an impact on body weight loss or gain in any of the groups. In the NMD, body weight gain due to fluid overload was more pronounced and associated with a lower age range. OS was similar between the groups and was not affected by OM. Conclusions: OM pattern was similar in pediatric patients with or without MD, but the factors that determined these oral lesions were different. There were disparities in body weight changes between the two groups, and these changes were not associated to OM. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Oral care and photobiomodulation protocol for the prevention of traumatic injuries and lip necrosis in critically ill patients with COVID-19: an observational study
- Author
-
de Paula Eduardo, Fernanda, Gobbi, Marcella Ferreira, Bergamin, Livia Goron, Migliorati, Cesar Augusto, and Bezinelli, Leticia Mello
- Published
- 2021
- Full Text
- View/download PDF
8. Salivary SARS-CoV-2 load reduction with mouthwash use: A randomized pilot clinical trial
- Author
-
Eduardo, Fernanda de Paula, Corrêa, Luciana, Heller, Debora, Daep, Carlo Amorin, Benitez, Carlos, Malheiros, Zilson, Stewart, Bernal, Ryan, Maria, Machado, Clarisse Martins, Hamerschlak, Nelson, Rebello Pinho, João Renato, and Bezinelli, Letícia Mello
- Published
- 2021
- Full Text
- View/download PDF
9. Efficacy of mouthrinses in reducing oral SARS-COV-2 load: a review.
- Author
-
PANNUTI, Claudio Mendes, dos REIS, Isabella Neme Ribeiro, SOUZA, Nathalia Vilela, SOUTO, Maria Luisa Silveira, SILVA, Carlos Guillermo Benítez, BEZINELLI, Leticia Mello, MACHADO, Clarisse Martins, ROMITO, Giuseppe Alexandre, and VILLAR, Cristina Cunha
- Subjects
SARS-CoV-2 ,CETYLPYRIDINIUM chloride ,VIRAL load ,HYDROGEN peroxide ,CHLORHEXIDINE - Abstract
Accumulated evidence has shown that the oral cavity may be an important reservoir for SARS-CoV-2. Some authors have suggested that the use of mouthrinses could reduce SARS-CoV-2 viral load in the saliva. Thus, the aim of this review was to synthesize evidence about the efficacy of mouthrinses in reducing the salivary viral load of SARS-CoV-2. 2. Nine randomized controlled trials (RCTs) have investigated the efficacy of different mouthrinses in reducing salivary SARS-CoV-2 loads. Various active ingredients have been tested in these trials: 0.5%,1% and 2% povidone-iodine, 0.2% and 0.12% chlorhexidine (CHX), 0.075% cetylpyridinium chloride (CPC), 0.075% CPC with Zinc lactate, 1% and 1.5% hydrogen peroxide (HP), 1.5% HP + 0.12% CHX and ß-cyclodextrin and citrox. The studies reported an intra-group reduction in the salivary levels of the virus, when compared with the baseline. However, the majority of these trials failed to demonstrate a significant inter-group difference between active groups and the control group relative to the decrease in salivary SARS-CoV-2 loads. Although promising, these results should be confirmed by larger trials. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Oral mucositis in pediatric patients undergoing hematopoietic stem cell transplantation: Clinical outcomes in a context of specialized oral care using low-level laser therapy
- Author
-
Eduardo, Fernanda de Paula, Bezinelli, Leticia Mello, de Carvalho, Danielle Lima Corrêa, Lopes, Roberta Marques da Graça, Fernandes, Juliana Folloni, Brumatti, Melina, Vince, Carolina Sgaroni Camargo, de Azambuja, Alessandra Milani Prandini, Vogel, Cristina, Hamerschlak, Nelson, and Correa, Luciana
- Published
- 2015
- Full Text
- View/download PDF
11. Oral lesions and saliva alterations of COVID‐19 patients in an intensive care unit: A retrospective study.
- Author
-
Eduardo, Fernanda de Paula, Bezinelli, Leticia Mello, Gobbi, Marcella Ferreira, Bergamin, Livia Goron, de Carvalho, Danielle Lima Correa, and Corrêa, Luciana
- Subjects
COVID-19 ,INTENSIVE care patients ,BRUISES ,ORAL mucosa ,CURRICULUM ,SALIVA - Abstract
Aim: To detect the type and frequency of oral lesions and clinical conditions suggestive of saliva alterations in COVID‐19 patients in an intensive care unit (ICU), as well as to describe the patient´s management in each case Methods: Information about oral conditions and mechanical ventilation was collected from oral medicine records of COVID‐19 patients in an ICU (n = 519) Results: From the total collected, 472 patients (90.9%) were examined by the oral medicine staff. In 242/472 patients (51.3%), alterations in the oral cavity were noted. The most frequent changes were mechanical trauma (18.1%, derived mainly from intubation), vascular/coagulation disturbances (24.1%, petechiae, bruises, varicoses, and oral bleeding), and saliva alterations (24.4%, dry mouth, and sialorrhea). Infectious lesions were mentioned in the oral medicine records (16.9%), most associated with a viral infection (15.7%), mainly herpesvirus. Improved oral change protocols included oral hygiene, use of specific medications, and laser therapy Conclusion: COVID‐19 patients in the ICU often showed dryness in the oral and mucosa oral lesions related to vascular/coagulation disturbances, and mechanical trauma derived from orotracheal tube. An oral medicine staff must be aligned with the ICU multidisciplinary team to manage COVID‐19 patients, as well as to establish diagnoses and oral cavity treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Severe oral ulcerative and lichenoid lesions associated with adrenal insufficiency in a patient treated with nivolumab: Report of a case and review of literature.
- Author
-
Gobbi, Marcella Ferreira, Eduardo, Fernanda de Paula, Bezinelli, Leticia Mello, de Carvalho, Danielle Lima Correa, Monção do Vale, Silvana Kelly, and Corrêa, Luciana
- Subjects
ADRENAL insufficiency ,NIVOLUMAB ,NON-small-cell lung carcinoma ,LITERATURE reviews ,IMMUNE checkpoint inhibitors ,EXANTHEMA - Abstract
Nivolumab, an antibody against anti‐programmed death type 1, has been used for treatment of advanced non‐small cell lung cancer with improvement of overall survival. Usually, diarrhea, cutaneous rash, and pruritus are reported as the most common immune‐related adverse effects of nivolumab therapy. Oral lesions and secondary adrenal insufficiency sometimes occur but usually are rare events. We report a case of a patient treated with nivolumab who then showed persistent oral ulcerative and lichenoid lesions, which were refractory to topical corticosteroids. The oral lesions were concomitant to nivolumab‐induced adrenal insufficiency. These adverse events led to nivolumab discontinuation, which favored oral lesion healing and adrenal insufficiency remission. Through a brief review of the literature concerning nivolumab toxicity in the oral cavity, we discuss the clinical aspect and management of these lesions. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Retrospective study of the digestive tract mucositis derived from myeloablative and non-myeloablative/reduced-intensity conditionings with busulfan in hematopoietic cell transplantation patient.
- Author
-
Eduardo, Fernanda P., Bezinelli, Leticia Mello, Gobbi, Marcella, Rosin, Flavia C. P., Carvalho, Danielle L. C., Ferreira, Mariana Henriques, da Silva, Cinthya Correa, Hamerschlak, Nelson, and Corrêa, Luciana
- Subjects
- *
MUCOSITIS , *BUSULFAN , *RETROSPECTIVE studies , *DIGESTIVE system diseases , *HEMATOPOIETIC stem cell transplantation , *TOTAL parenteral feeding , *GRAFT versus host disease , *IMMUNOSUPPRESSION , *IMMUNOSUPPRESSIVE agents , *RESEARCH funding - Abstract
Busulfan is a major component of chemotherapy conditioning in hematopoietic cell transplantation (HCT). This alkylating agent is highly toxic at myeloablative doses, exposing HCT patients to risks of mortality. Non-myeloablative (NMA) and reduced-intensity conditioning (RIC) using busulfan have shown impaired toxicity. However, the toxicity of NMA/RIC in the digestive tract is poorly described. This study aimed to characterize the mucositis in the oral cavity (OM), oropharynx/esophagus, and gastrointestinal tract derived from conditionings with myeloablative and non-myeloablative doses of busulfan. We retrospectively retrieved clinical data of HCT patients (n = 100) who underwent myeloablative conditioning (MAC) or NMA/RIC with busulfan. Frequency and time duration of mucositis in the oral cavity and oropharynx/esophagus, diarrhea, and prescription of total parenteral nutrition (TPN) and opioids were also collected. OM severity (p = 0.009) and time duration of mucositis in oropharynx/esophagus (p = 0.022) were frequently higher in MAC than NMA/RIC. A myeloablative dose of busulfan was a risk factor for OM grade ≥ 2 (OR = 4.8, p = 0.002) and for mucositis in oropharynx/esophagus ≥ 5 days (OR = 2.64, p = 0.035). A longer duration of mucositis in the oropharynx/esophagus was also associated with an increase in the prescription of opioids (OR = 7.10, p < 0.001).Overall survival (OS) in MAC was significantly higher than that in NMA/RIC (p = 0.017). No variables related to mucositis interfere significantly in OS. In conclusion, myelosuppression in busulfan-based regimens are predisposed to a high risk for severe OM and to prolonged mucositis in the oropharynx/esophagus. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
14. Impact of Oral and Gastrointestinal Mucositis on Body Weight Alterations during Hematopoietic Stem Cell Transplantation.
- Author
-
Eduardo, Fernanda de Paula, Bezinelli, Leticia Mello, Gobbi, Marcella Ferreira, Pereira, Andrea Z., Vogel, Cristina, Hamerschlak, Nelson, and Corrêa, Luciana
- Subjects
- *
AUTOGRAFTS , *BODY weight , *DIARRHEA , *FORECASTING , *HEMATOPOIETIC stem cell transplantation , *HOMOGRAFTS , *PROBABILITY theory , *SEX distribution , *STOMATITIS , *SURVIVAL , *WEIGHT loss , *WEIGHT gain , *GASTROINTESTINAL mucosa , *STATISTICAL significance , *ODDS ratio , *DISEASES - Abstract
The aim of this study was to evaluate whether digestive tract mucositis is a predictive factor for body weight (BW) alterations during hematopoietic stem cell transplantation (HSCT). Data about characteristics of transplantation, initial nutritional conditions and gastrointestinal mucositis were collected from adult patients (n= 105) who underwent autologous and allogeneic HSCT. Oral mucositis (OM) was not a predictive factor for BW loss, but it was an independent factor for BW gain in autologous HSCT (β = 0.329,P= 0.021). Busulfan-fludarabine conditioning regimen (β = 1.531,P= 0.011) and gender (β = 1.109,P= 0.038) were significant independent risk factors for BW loss in allogeneic HSCT. Overall survival (OS) was significantly affected by the duration of OM in autologous HSCT (HR = 1.243,P= 0.008). In allogeneic HSCT, BW loss (HR = 1.308,P= 0.049) and diarrhea (HR = 1.139,P= 0.012) interfered significantly with OS. In conclusion, OM was not a risk factor for BW loss, but it influenced BW gain and had a negative impact on OS in autologous HSCT patients. Intestinal mucositis explained partially the BW loss and had a negative impact on OS in allogeneic HSCT. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
15. Efficacy of cryotherapy associated with laser therapy for decreasing severity of melphalan-induced oral mucositis during hematological stem-cell transplantation: a prospective clinical study.
- Author
-
Paula Eduardo, Fernanda, Bezinelli, Leticia Mello, Graça Lopes, Roberta Marques, Nascimento Sobrinho, Jairo Jose, Hamerschlak, Nelson, and Correa, Luciana
- Subjects
MULTIPLE myeloma treatment ,COLD therapy ,HEMATOPOIETIC stem cell transplantation ,MEDICAL lasers ,LONGITUDINAL method ,MULTIPLE myeloma ,STOMATITIS ,TIME ,TREATMENT effectiveness ,RETROSPECTIVE studies ,HEMATOLOGIC malignancies ,MELPHALAN ,THERAPEUTICS - Abstract
Melphalan followed by hematopoietic stem-cell transplantation (HSCT) is the standard treatment for multiple myeloma and other hematopoietic neoplasms. However, high doses of melphalan cause severe oral mucositis (OM). The objective was to verify the efficacy of cryotherapy plus laser therapy on reduction of OM severity. HSCT patients undergoing melphalan chemotherapy (n = 71) were randomly divided into two groups according to OM treatment: oral cryotherapy performed with ice chips for 1 h 35 min followed by low-level laser therapy (InGaAIP, 660 nm, 40 mW, 6 J/cm(2) ) (n = 54) and laser therapy alone with the same protocol (n = 17). A control group (n = 33) was composed of HSCT patients treated with melphalan who received no specific treatment for OM. OM scores and clinical information were collected from D0 to D + 11. The cryotherapy/laser therapy group showed the lowest OM scores (maximum Grade I) and the lowest mean number of days (8 days) with OM in comparison with the other groups (p < 0.001). OM Grades III and IV were present with high frequency only in the control group. The association of cryotherapy with laser therapy was effective in reducing OM severity in HSCT patients who underwent melphalan conditioning. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
16. Taste Alteration Analysis during Hematopoietic Steam Cells Transplantation.
- Author
-
Ferreira, Mariana Henriques, Eduardo, Fernanda de Paula, Bezinelli, Leticia Mello, Gobbi, Marcella Ferreira, Lopes, Roberta Marques, Voguel, Cristina, Sodre, Lidiane Soares, da Silva, Cinthya Correa, Pereira, Andrea Z, Hamerschlak, Nelson, and Corrêa, Luciana
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *CLINICAL trials , *QUALITY of life , *NEUTROPENIA , *MUCOSITIS , *TREATMENT effectiveness - Abstract
Taste changes during hematopoietic steam cells transplantation (HSC) are often acknowledged after the transplantation, however little is known about which flavors and what types of perception changes are experienced by patients during this treatment. The aim of this study was to characterize taste and taste buds atrophy alterations present during the HSC, as well as to verify if there is association among these alterations and clinical variables related to the transplant and oral mucosal toxicity. The impact of taste and oral mucosa alterations on patients' quality of life was also evaluated. We selected 54 patients holding autologous and allogenic HSC, who underwent taste acuity tests prior to conditioning (T0), during neutropenia (T1) and engraftment (T2). It was carried out an acuity test in the perception of sweet, bitter, sour and salty flavors, offered in solutions containing low and high concentrations of watery substances stimulating these flavors. Patients were also submitted to oroscopy for evaluation of oral mucositis and taste buds atrophy. It was found that 69% of patients suffered taste alteration in T1 and 70% in T2. Also flavor intensity was wrongly reported more times by patients in T1 (79%) and T2 (78%) than prior to conditioning. Taste buds atrophy was observed in 74% of patients at T1 and 78% at T2, being correlated to change in the flavor (p = 0.037) at T2. Taste buds atrophy was inversely correlated to TBI treatment in their conditioning, with 42% of patients affected (p = 0.036). Finally, patients suffering mucositis for 7 days or longer presented more taste buds atrophy (p = 0.048).Conclusion: The oral mucositis duration, the conditioning regime and taste buds atrophy are factors that may be associated with greater taste alteration in patients submitted to HSC. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. Data Manager in a Bone Marrow Transplant Team in Brazil: Training, Certifications, International Connections and Dissemination.
- Author
-
Silva, Cinthya Correa, Vogel, Cristina, Waisbeck, Tania Michele, Ribeiro, Andreza Feitosa, Sodre, Lidiane Soares, Kondo, Andrea, Torres, Margareth, Eduardo, Fernanda de Paula, Bezinelli, Leticia Mello, Fernandes, Juliana Folloni, and Hamerschlak, Nelson
- Subjects
- *
GRAFT versus host disease , *NURSING databases , *BONE marrow , *HEMATOPOIETIC stem cells , *STEM cell transplantation , *CELLULAR therapy , *ALEMTUZUMAB - Abstract
Regular analysis of demographic, clinical and outcome data is indispensable for ensuring and maintaining quality in a hematopoietic stem cell transplant (HSCT) center. For this, data needs to be extracted accurately. Organization accreditations such as FACT (Foundation for the Accreditation of Cellular Therapy) require submission of data to the US (CIBMTR) or the European (EBMT) Registries correctly. Due to discrepancies found between medical charts data and the data submitted to CIBMTR in the first FACT accreditation cycle (2012), our HSCT center decided to hire a dedicated data manager. We describe here the training and performance of the data manager in the process of collecting and transferring HSCT data to national and international registries. The professional hired as data manager received internal and external training. Externally, she attended national and international congresses and visited the CIBMTR (2016). Internally, she first received training by the clinical team about the forms to be filled in. Together with the HSCT multi-professional team, they evaluated the data collection process and defined which data should appear in the medical records. Appropriate outcomes were defined for data analysis based on literature searches, the FACT requirements and the need of the clinical staff, and the data manager was trained in data analysis using R. The clinical team together with data manager developed templates appropriate for the clinical follow-up of patients, such as the Dentistry to collect data on mucositis. The quality nurse developed a regular internal auditing system. One of the results was the reduction of three hours in filling out the forms (TED 2400). From the structuring, organization and updating of the database, it was possible to obtain relevant indicators on survival and cumulative incidence of acute and chronic graft versus host disease, transplant-related mortality and disease relapse. These are used by the HSCT team in clinical rounds and in critical analyses of the program performance. In re-accreditations (2015 and 2018) after hiring and training, no non-compliance was identified in item B9, related to the insertion and submission of transplant data. In 2017, the clinical team designed, with the data manager, an ethically-approved multicenter study until 2027, about on transplant-related outcomes, currently with 19 centers in Brazil that sending data to CIBMTR. Training of the data manager at our HSCT center (a profession not official in Brazil) allowed the development of strategies and tools that resulted in greater accuracy in data collection and analysis, and FACT-compliant. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
18. Oxidative Stress and DNA Damage in Keratinocytes Treated with Bussulphan Veiculated in Artificial Saliva.
- Author
-
de Carvalho, Danielle Lima Correa, Ferreira, Mariana Henriques, de Paula Eduardo, Fernanda, Bezinelli, Leticia Mello, Rosin, Flávia Cristina Perillo, Waisbeck, Tania Michele, Voguel, Cristina, Hamerschlak, Nelson, and Corrêa, Luciana
- Subjects
- *
OXIDATIVE stress , *DNA damage , *HEMATOPOIETIC stem cell transplantation , *ARTIFICIAL saliva , *KERATINOCYTES - Abstract
During conditioning of hematopoietic stem cell transplantation, numerous chemotherapeutics are used, among them, busulfan (BU). This is an alkylating agent that generates intense toxicity induced by oxidative stress, which can lead to DNA damage and cause oral mucositis (MO). BU is found at salivary levels close to plasma levels, but it is not known whether salivary concentrations are toxic as much as plasma to the oral cavity. This work aimed to analyze oxidative stress and possible DNA damage in keratinocytes exposed to BU found in salivary doses. Human keratinocytes were cultured and the following groups were established: Control (no treatment), Control Saliva (exposure to artificial saliva) and BU (exposure to BU carried in saliva at 4.0, 4.5, 5.0 and 5.5 μg / mL). The cell viability and the number of cells with DNA fragmentation were evaluated by TUNEL assay, as well as the level of oxidative stress by quantification of sequestration of the radical DPPH, superoxide dismutase (SOD), catalase (CAT) and level of lipid peroxidation (PL). Through the comet assay, the percentage of fragmented DNA was evaluated. The effect of BU on keratinocytes was dose-dependent; the dose of 5.5 μg / mL without vehicle with saliva generated 76% cellular viability, differing from the Control group (p < 0.05); when the BU was delivered in saliva, all doses generated less viability than the BU without saliva (p < 0.001). In the TUNEL analysis, salivary BU treatment caused a higher frequency of cells with DNA fragmentation (p < 0.05 compared to controls), as well as lower sequestration potential of the DPPH radical (p < 0.05 compared to the controls). Catalase activity was higher in the BU group (p < 0.01 compared to the controls). Exposure to BU also generated a higher percentage of fragmented DNA (p < 0.05 compared to Control). It was concluded that the salivary concentration of BU is toxic to keratinocytes, inducing oxidative stress and increased DNA damage. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.